Although COVID-19 mRNA-1273 vaccination was associated with increased risk for anaphylaxis, myocarditis, and pericarditis, no other reported adverse events of special interest were considered related ...

CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new ...

Current data reveals no significant differences in the antibody responses to the XBB.1 variant of SARS-CoV-2 between the BA.4/BA.5 and BA.1 vaccines. While the precise formulation of future vaccine ...

In an observational study involving nearly 440,000 veterans, both the BNT162b2 vaccine and the mRNA-1273 vaccine were highly effective at preventing infection, hospitalization, and death from Covid-19 ...

OBJECTIVESTo evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination. DESIGNTest negative ...

NEW YORK -- Moderna is seeking emergency use authorization from the US Food and Drug Administration for its Covid-19 vaccine for children 6 months through 5 years of age, the company said Thursday.

A recent study published in the journal Scientific Reports evaluated the durability of neutralizing antibody (nAb) responses induced after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ...

ModernaMRNA announced positive results from the pivotal phase III NextCOVE study evaluating mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, in individuals aged 12 years and older.

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older ...